Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2020

View Archived Issues

OCT1 overexpression tied to poor prognosis in DLBCL

Singapore HSA approves CANbridge's IND for CAN-106 for complement dysregulation diseases

CTA approved in Belgium for phase l/lla study of oncolytic virus BT-001 in solid tumors

BI-767551 enters phase I/IIa development

ImmuneMed progresses hzVSF-v13 into phase II clinical development in various countries

Initiation of phase I study evaluating MB-101 in patients with leptomeningeal brain tumors

Fintepla approved in Europe for the treatment of seizures in Dravet syndrome

Enanta Pharmaceuticals divulges compounds for HBV infection

Sage Therapeutics has patented GABA(A) receptor modulators

Pfizer/BioNTech COVID-19 vaccine receives conditional marketing authorization in Europe

Celgene synthesizes new CKI-alpha degradation inducers

Aligos Therapeutics presents HBV and HDV antivirals

City of Hope National Medical Center divulges new CARs for treating T-cell lymphoma

EC grants approval for Libmeldy gene therapy as treatment of early-onset MLD

Phase III HOPE-B study of etranacogene dezaparvovec meets first coprimary endpoint

Endothelial stress products in circulating blood as biomarkers for COVID-19

Stem cell-derived vesicles protective against neonatal hemorrhage

Menin/KMT2A inhibitor KO-539 shows encouraging preliminary results for treating R/R AML

HX-008 plus chemotherapy demonstrates promising safety and efficacy in first-line mTNBC

BioCryst reports encouraging phase I data on BCX-9250 for fibrodysplasia ossificans progressiva

BioEclipse initiates first-in-human study of CRX-100 to treat refractory solid tumors

Sellas reports initial data on galinpepimut-S with checkpoint inhibitors for ovarian cancer and MPM

Annexon begins phase II/III study of ANX-005 for Guillain-Barre syndrome

CureVac opens phase III study of COVID-19 vaccine CVnCoV in healthcare workers

DTRM-555 meets primary endpoint in first-in-human study with patients with B-cell lymphomas

OSE initiates phase II trial of OSE-127 in ulcerative colitis

European Commission approves cabotegravir and rilpivirine long-acting injectable for HIV

Polyphor cleared to begin phase I study of inhaled murepavadin

Topline ACCOLADE data for avacopan in C3 glomerulopathy

Phase II study of AZR-MD-001 for contact lens discomfort meets primary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...